ABL1 and acute lymphoblastic leukemia: Although first- and second-generation TKIs, such as imatinib, nilotinib, and dasatinib, demonstrate improved outcomes in patients with CML and Ph+ acute lymphoblastic leukemia, a subset of patients with BCR-ABL mutations, particularly the T315I mutation, exhibit resistance to these TKIs [3].